Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Clinical Medicine (London, England)|June 3, 2015
Infectious causes of fever of unknown originAlastair C McGregor, David A Moore
Clinical Medicine (London, England)|February 5, 2015
Gastrointestinal symptoms in travellersAlastair C McGregor, Stephen G Wright
Current Opinion in Infectious Diseases|April 18, 2013
Prospects for prevention of Salmonella infection in children through vaccinationAlastair C McGregor, Claire S Waddington, Andrew J Pollard
Transactions of the Royal Society of Tropical Medicine and Hygiene|July 24, 2012
Geographic, symptomatic and laboratory predictors of parasitic and bacterial causes of diarrhoea in travellersAlastair C McGregor, Christopher J M Whitty, Stephen G Wright
BMC Infectious Diseases|June 5, 2019
Clinical characteristics and treatment outcomes in a cohort of patients with pyogenic and amoebic liver abscessLorna Neill, Frances Edwards, Simon M Collin, et al.
The American Journal of Tropical Medicine and Hygiene|June 21, 2019
Clinical and Diagnostic Features of 413 Patients Treated for Imported Strongyloidiasis at the Hospital for Tropical Diseases, LondonDamien K Ming, Margaret Armstrong, Patricia Lowe, et al.
The Journal of Infection|August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trialLeila Janani, Alasdair P S Munro, Annie Wright, et al.
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
The Lancet. Infectious Diseases|May 13, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialAlasdair P S Munro, Shuo Feng, Leila Janani, et al.
The Journal of Infection|April 11, 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Shuo Feng, et al.
Pageof 2